The present invention relates to novel chemotherapeutics, substituted bithazoles, with a potentially safer therapeutic profile. Discovered compounds inhibit human DNA topoisomerase II via an alternative mechanism, thus avoiding the DNA damage. This lowers the chances of cardiotoxicity and induction of secondary malignancies, side effects associated with clinically used topo II drugs. Compounds can be used as a standalone chemotherapy or in combination with other anticancer drugs.